Avelumab is a human anti-PD-L1 IgG1 antibody, which blocks the interaction with PD-1 to potentiate T-cell cytotoxicity against tumor cells. Avelumab is approved by the FDA for the treatment of patients with two different types of cancer. The incidence of binding and neutralizing antibodies against avelumab was found to be low with no apparent impact on clinical pharmacokinetics, safety, or efficacy.
